{
    "clinical_study": {
        "@rank": "122536", 
        "arm_group": {
            "arm_group_label": "Liver-only metastases", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, single arm, multicenter study will evaluate the resection rate in patients\n      with colorectal cancer and previously untreated unresectable liver-only metastases after\n      adding Avastin (bevacizumab) to 5-FU based doublet chemotherapy in the neoadjuvant setting.\n      Patients will receive standard 5-FU based chemotherapy plus Avastin 5 mg/kg every 2 weeks\n      for a maximum of 12 cycles combined pre- and postoperatively unless they experience\n      progressive disease or unacceptable toxicity."
        }, 
        "brief_title": "A Study of Avastin (Bevacizumab) in Combination With 5-FU Based Doublet Chemotherapy in Patients With Colorectal Cancer And Previously Untreated Unresectable Liver-Only Metastases", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer, Neoplasm Metastasis", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult Chinese patients, 18-75 years of age\n\n          -  Histologically confirmed adenocarcinoma in colon or rectum with primary lesion\n             surgically removed\n\n          -  Previously untreated unresectable liver-only metastases\n\n          -  Liver lesions determined to be unresectable by multidisciplinary team (MDT,\n             consisting of experienced hepatic surgeons, medical oncologist and radiologist).\n             Guidelines used to determine unresectability includes:\n\n          -  R0 treatment infeasible with resection\n\n          -  cannot spare two adjacent liver segments\n\n          -  retention of liver volume <30%\n\n          -  vascular flow and biliary drainage cannot be preserved\n\n          -  No previous treatment against liver metastases, including chemotherapy, surgery,\n             radiotherapy, TACE and target therapy\n\n          -  Adequate hematological, renal and hepatic function\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\n          -  Life expectancy > 3 months\n\n        Exclusion Criteria:\n\n          -  The relapse has occurred within 6 months of completion of the adjuvant treatment\n\n          -  Expected impossible to achieve R0 resection and/or gain 30% residual liver volume\n             even with responsive neoadjuvant therapy\n\n          -  Patient cannot tolerate the surgery\n\n          -  Other malignancies in the past 5 years, except for curatively treated basal cell\n             carcinoma of the skin and/or in situ carcinoma of the cervix\n\n          -  Any extrahepatic metastases and/or recurrence of the primary tumor\n\n          -  Any residual toxicity from previous chemotherapy (except alopecia) of NCI CTC v.4.0\n             grade 2\n\n          -  Hypertension crisis or encephalopathy\n\n          -  Pregnant or lactating women\n\n          -  Clinically significant cardiovascular disease\n\n          -  Evidence of bleeding diathesis or coagulopathy\n\n          -  Current or recent (within 10 days of study drug initiation) use of full dose of\n             aspirin, clopidrogel or warfarin\n\n          -  History or evidence of CNS disease (e-g- primary brain tumor, seizures not controlled\n             with standard medical therapy, any brain metastases, or history of stroke)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695772", 
            "org_study_id": "ML28419"
        }, 
        "intervention": [
            {
                "arm_group_label": "Liver-only metastases", 
                "description": "5 mg/kg every 2 weeks, up to 12 cycles pre- and postoperatively", 
                "intervention_name": "bevacizumab [Avastin]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Liver-only metastases", 
                "description": "standard 5-FU based doublet chemotherapy", 
                "intervention_name": "5-FU based doublet chemotherapy", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100142"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510060"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "zip": "310009"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China", 
                        "zip": "150001"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200032"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "zip": "110042"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "zip": "430022"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Single-arm, Pilot Study of 5-FU Based Doublet Chemotherapy Plus Bevacizumab as Neoadjuvant Therapy for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28419 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: State Food and Drug Administration (SFDA)"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Complete resection rate (R0) in metastatic colorectal cancer patients with previously unresectable liver-only metastases", 
            "safety_issue": "No", 
            "time_frame": "approximately 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695772"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate (ORR), tumor assessments according to RECIST v.1.1 criteria", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Progression-free survival (PFS) for all patients enrolled in the study", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Disease-free survival (DFS) for patients who achieve complete resection", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}